Precipio (NASDAQ:PRPO) Shares Cross Below 200-Day Moving Average – Here’s WhyDefense World · 2 days ago
Precipio: Management Dreams Big, Institutions Have A Toe InSeeking Alpha · Oct 12, 2026
Precipio (NASDAQ:PRPO) Share Price Crosses Below 200 Day Moving Average – What’s Next?Defense World · Oct 7, 2026
PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?Zacks Investment Research · Sep 22, 2026
Analyzing Precipio (NASDAQ:PRPO) and AdaptHealth (NASDAQ:AHCO)Defense World · Sep 21, 2026
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?Zacks Investment Research · Aug 24, 2026Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$2.00 | -$0.12 | Beat |
| May 18, 2026 | – | -$0.81 | |
| Mar 30, 2026 | – | $0.33 | |
| Nov 14, 2025 | $0.74 | -$0.05 | Miss |
| Aug 13, 2025 | $0.74 | $0.05 | Miss |
| May 14, 2025 | $0.40 | -$0.59 | Miss |